News
CARs come in different makes and models
Credit: NIAID SAN FRANCISCO—CTL019, a chimeric antigen receptor (CAR) T cell targeting CD19, is not the only CAR in the production line....
News
CAR is feasible in majority of ALL patients, team says
Credit: Bill Branson SAN FRANCISCO—A chimeric antigen receptor (CAR) T-cell therapy is feasible in 90% of heavily pretreated or transplanted...
News
CAR produces durable responses in B-cell ALL
Credit: Charles Haymond SAN FRANCISCO—JCAR015, a chimeric antigen receptor (CAR) T-cell therapy, can produce durable responses in patients with B...
News
Classic HL vulnerable to PD-1 blockade therapy
SAN FRANCISCO—Two monoclonal antibodies that block the programmed death-1 (PD-1) pathway are showing promise in early phase trials in relapsed/...
News
Brentuximab combinations highly active in Hodgkin lymphoma
Photo courtesy of ASH SAN FRANCISCO—Two recent studies have shown combination therapy with brentuximab vedotin to be highly active in newly...
News
Study confirms IDH2 as therapeutic target in AML, MDS
in the Moscone Center SAN FRANCISCO—The first-in-human study of AG-221 has confirmed IDH2 as a therapeutic target in acute myeloid leukemia (AML...
News
Blinatumomab confirmed as treatment option in MRD+ ALL
SAN FRANCISCO—The first international, multicenter trial in acute lymphoblastic leukemia (ALL) using minimal residual disease (MRD) as a criterion...
News
Researchers show CTL019 cells proliferate and persist
Researchers at the University of Pennsylvania, working with CTL019 cells, are beginning to see both of these phenomena in children with relapsed,...
News
Two activin receptor fusion proteins show promise in anemia
site of the ASH Annual Meeting Photo courtesy of ASH SAN FRANCISCO—Two activin receptor fusion proteins, luspatercept and sotatercept, increased...
News
First randomized evidence for kinase inhibitor use in AML
Photo courtesy of ASH SAN FRANCISCO—Researchers have presented the first randomized evidence that kinase inhibitors are effective in the...
News
More isn’t always better with daunorubicin induction in AML
Photo courtesy of ASH SAN FRANCISCO—Results regarding daunorubicin escalation in induction for patients with acute myeloid leukemia (AML) have...
News
New agents challenge role of transplant in high-risk CLL
NEW YORK—The role of allogeneic hematopoietic stem cell transplant (HSCT) for patients with high-risk chronic lymphocytic leukemia (CLL) is...
News
Panobinostat demonstrates ‘profound’ synergy with bortezomib
NEW YORK—Calling the synergy with the proteasome inhibitor “profound,” Paul G.
News
Chlorambucil’s role in untreated CLL debated
NEW YORK—With both the pro and con positions drawing on data from the phase 3 CLL11 trial, two speakers at the Lymphoma & Myeloma2014 congress...
News
Armored CAR T cells next on the production line
NEW YORK—Chimeric antigen receptor (CAR) T cells have “remarkable” activity, according to a speaker at the NCCN 9th Annual Congress: Hematologic...